Liquidia Corp (LQDA) Q2 2024 Earnings Call Highlights: Navigating Challenges and Opportunities ...

GuruFocus News
4 min read

In This Article:

  • Revenue: $3.7 million for Q2 2024, down from $4.8 million in Q2 2023.

  • Cost of Revenue: Increased to $1.5 million in Q2 2024 from $0.7 million in Q2 2023.

  • Research and Development Expenses: $9.4 million in Q2 2024, down from $17.7 million in Q2 2023.

  • General and Administrative Expenses: $20 million in Q2 2024, up from $9.2 million in Q2 2023.

  • Net Loss: $27.9 million for Q2 2024, or $0.37 per share, compared to $23.5 million, or $0.36 per share, in Q2 2023.

  • Cash on Hand: $133 million at the end of Q2 2024.

Release Date: August 07, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Liquidia Corp (NASDAQ:LQDA) is actively preparing for the potential launch of YUTREPIA, with commercial teams ready to distribute upon FDA approval.

  • The ASCENT study of YUTREPIA in PH-ILD patients is progressing well, with positive preliminary feedback from physicians.

  • The company has received favorable scientific advice from the European Medicines Agency for its L606 trial design, aligning with FDA feedback.

  • Liquidia Corp (NASDAQ:LQDA) ended the second quarter of 2024 with a strong cash position of $133 million, supporting its corporate objectives.

  • The market opportunity for inhaled treprostinil is significant, with potential growth from a $1.5 billion run rate to over $3 billion.

Negative Points

  • Revenue for the second quarter of 2024 decreased to $3.7 million from $4.8 million in the same quarter of 2023, primarily due to lower sales quantities.

  • The company reported a net loss of $27.9 million for the second quarter of 2024, compared to a net loss of $23.5 million in the previous year.

  • General and administrative expenses increased significantly to $20 million in Q2 2024, up from $9.2 million in Q2 2023, driven by personnel and legal expenses.

  • There are ongoing uncertainties regarding the FDA's decision on the YUTREPIA NDA, with no specific timeline provided for approval.

  • The company faces legal challenges, including ongoing litigation related to YUTREPIA, which could impact future operations and financial performance.

Q & A Highlights

Q: Can you explain why higher inhaled treprostinil exposure is beneficial for PAH and PH-ILD? A: Roger Jeffs, CEO, explained that prostacyclins allow for continuous titration to effect, which is crucial for progressive diseases like PAH and PH-ILD. YUTREPIA offers the benefits of parenteral and oral products with fewer systemic side effects, allowing for higher dosing flexibility and effectiveness. Rajeev Saggar, CMO, added that higher doses have shown improved outcomes in clinical observations, making YUTREPIA a potentially best-in-class treatment.

Recommended Stories